Journal article icon

Journal article

Achieving systemic delivery of oncolytic viruses

Abstract:

Introduction: Oncolytic virotherapy is a selective and powerful tool for cancer treatment. Studies proving the ability of oncolytic viruses (OVs) to target and rapidly kill cancer cells have led to approval of H101 and Imlygic®. Both these OVs are restricted to intratumoral administration into cancer lesions. Despite promising preclinical results, systemic delivery of OV has shown limited success in patients due to a knockdown in infectivity, as a result of rapid immune-me...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1080/17425247.2019.1617269

Authors


More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Engineering Science
Oxford college:
St Cross College
Role:
Author
ORCID:
0000-0003-4508-4802
Publisher:
Taylor and Francis Publisher's website
Journal:
Expert Opinion on Drug Delivery Journal website
Volume:
16
Issue:
6
Pages:
607-620
Publication date:
2019-05-30
Acceptance date:
2019-05-07
DOI:
EISSN:
1744-7593
ISSN:
1742-5247
Source identifiers:
1071413
Language:
English
Keywords:
Pubs id:
pubs:1071413
UUID:
uuid:bbb28dfa-f1d1-4133-917f-ecefbd80e627
Local pid:
pubs:1071413
Deposit date:
2019-11-12

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP